Patents by Inventor Gwo-Yu Chuang
Gwo-Yu Chuang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139309Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.Type: ApplicationFiled: January 14, 2022Publication date: May 2, 2024Applicant: ModernaTX, Inc.Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamiltion Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
-
Publication number: 20240101609Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: December 12, 2023Publication date: March 28, 2024Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servi, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20240100151Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.Type: ApplicationFiled: January 14, 2022Publication date: March 28, 2024Applicant: Moderna TX, Inc.Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamilton Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
-
Publication number: 20240018193Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: ApplicationFiled: September 11, 2023Publication date: January 18, 2024Applicant: The United State of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Patent number: 11845778Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: GrantFiled: July 16, 2021Date of Patent: December 19, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20230381293Abstract: Recombinant Norovirus Virus-Like Particles (VLPs) formed from recombinant Norovirus VP1 proteins, and methods of their use and production are disclosed. In several embodiments, the Recombinant Norovirus VLPs can be used to generate an immune response to Norovirus VP1 protein in a subject. In additional embodiments, an effective amount of the recombinant Norovirus VLPs can be administered to a subject in a method of inhibiting a Norovirus infection.Type: ApplicationFiled: October 14, 2021Publication date: November 30, 2023Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The University of North Carolina at Chapel Hill, Board of Regents, the University of Texas SystemInventors: Peter Kwong, Raffaello Verardi, Yaroslav Tsybovsky, Jason Gorman, Gwo-Yu Chuang, Li Ou, Lisa Lindesmith, Ralph Baric, George Georgiou, Inga Rimkute, Mario Roederer
-
Publication number: 20230338507Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: February 6, 2023Publication date: October 26, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
-
Publication number: 20230227512Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: ApplicationFiled: October 3, 2022Publication date: July 20, 2023Inventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry, Aliaksandr Druz
-
Patent number: 11602559Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: GrantFiled: October 3, 2017Date of Patent: March 14, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
-
Patent number: 11459360Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: GrantFiled: August 30, 2019Date of Patent: October 4, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry, Aliaksandr Druz
-
Publication number: 20220098286Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: December 14, 2021Publication date: March 31, 2022Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Patent number: 11236152Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: November 3, 2016Date of Patent: February 1, 2022Assignees: The United States of America, as represented by the Sectetary, Department of Health and Human Services, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20220024987Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: July 16, 2021Publication date: January 27, 2022Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20220002351Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: ApplicationFiled: September 17, 2021Publication date: January 6, 2022Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Patent number: 11136356Abstract: Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and methods of their use and production are disclosed. In several embodiments, the immunogen can be used to elicit an immune response to HIV-1 in a subject.Type: GrantFiled: October 16, 2018Date of Patent: October 5, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, John Mascola, Gwo-Yu Chuang, Hui Geng, Yongping Yang, Cheng Cheng, Jeffrey Boyington, Yen-Ting Lai
-
Patent number: 11130785Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: GrantFiled: July 2, 2018Date of Patent: September 28, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Patent number: 11078239Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: GrantFiled: October 25, 2017Date of Patent: August 3, 2021Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20210188921Abstract: Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and methods of their use and production are disclosed. In several embodiments, the immunogen can be used to elicit an immune response to HIV-1 in a subject.Type: ApplicationFiled: October 16, 2018Publication date: June 24, 2021Applicant: The United States of America, as represented by the Secretary,Department of Health and Human ServiceInventors: Peter Kwong, John Mascola, Gwo-Yu Chuang, Hui Geng, Yongping Yang, Cheng Cheng, Jeffrey Boyington, Yen-Ting Lai
-
Patent number: 10815295Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: July 24, 2018Date of Patent: October 27, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20200230229Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: October 3, 2017Publication date: July 23, 2020Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Michael Gordon Joyce, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong, Yongping Yang